The ORIGIN trial showed that insulin glargine neither increased nor decreased cardiovascular events compared to standard care
Clients in Katy and The Woodlands often explore this option when they want a more targeted strategy than eat less, move more, especially when stress, sleep, hormones, and age are working against them
Image: Shutterstock February 15, 2024 11:21 AM ESTUpdated February 16, 04:41 AM R&D In Focus Ayisha Sharma News Reporter Katherine Lewin News Reporter Novo Nordisk and Eli Lilly are set to make billions of dollars each year off their GLP-1s, but patients and prescribers are still eager for Sign up to read this article for free
GLP-1 drugs are a class of medications used to treat obesity and type 2 diabetes that include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)
doi:10.3945/jn.114.197533 Elsawy, Gehan, Osama Abdelrahman, and Amr Hamza